A clinical trial will examine an investigational drug’s (AZD5847) early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis, including individuals who are also infected with HIV but not yet taking antiretroviral treatmen.

Christine F. Sizemore, Ph.D., Richard E. Hafner, M.D., and Anthony S. Fauci, M.D., National Institute of Allergy and Infectious Diseases, National Institutes of Health